Akcea Therapeutics Inc (NASDAQ:AKCA) has earned a consensus recommendation of “Hold” from the eight analysts that are covering the firm, MarketBeat Ratings reports. Five research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $40.50.
A number of analysts have recently commented on AKCA shares. ValuEngine raised shares of Akcea Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, April 4th. Zacks Investment Research raised shares of Akcea Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, March 4th.
AKCA stock opened at $22.02 on Thursday. The stock has a market cap of $2.01 billion, a PE ratio of -8.04 and a beta of 1.63. The company has a debt-to-equity ratio of 0.04, a current ratio of 6.61 and a quick ratio of 6.61. Akcea Therapeutics has a 52 week low of $19.67 and a 52 week high of $40.75.
Akcea Therapeutics (NASDAQ:AKCA) last released its earnings results on Wednesday, May 8th. The company reported $0.34 EPS for the quarter, missing analysts’ consensus estimates of $1.24 by ($0.90). The company had revenue of $163.82 million for the quarter, compared to analysts’ expectations of $171.40 million. Akcea Therapeutics had a negative return on equity of 54.63% and a negative net margin of 79.88%. The firm’s revenue for the quarter was up 857.5% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.44) EPS. As a group, equities analysts anticipate that Akcea Therapeutics will post -0.63 EPS for the current fiscal year.
In related news, COO Jeff Marc Goldberg sold 30,000 shares of the business’s stock in a transaction dated Friday, April 5th. The shares were sold at an average price of $31.71, for a total transaction of $951,300.00. Following the transaction, the chief operating officer now directly owns 32,880 shares in the company, valued at $1,042,624.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Paula Soteropoulos sold 31,787 shares of the business’s stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $32.11, for a total transaction of $1,020,680.57. Following the transaction, the chief executive officer now owns 30,000 shares in the company, valued at $963,300. The disclosure for this sale can be found here. Insiders have sold 111,787 shares of company stock valued at $3,557,481 in the last three months. Corporate insiders own 3.64% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of AKCA. Quantamental Technologies LLC acquired a new position in Akcea Therapeutics during the first quarter worth about $74,000. BNP Paribas Arbitrage SA boosted its position in Akcea Therapeutics by 842.0% during the first quarter. BNP Paribas Arbitrage SA now owns 3,165 shares of the company’s stock worth $90,000 after acquiring an additional 2,829 shares during the last quarter. Marshall Wace North America L.P. acquired a new position in Akcea Therapeutics during the first quarter worth about $106,000. SG Americas Securities LLC acquired a new position in Akcea Therapeutics during the fourth quarter worth about $116,000. Finally, Metropolitan Life Insurance Co. NY boosted its position in Akcea Therapeutics by 350.4% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 5,008 shares of the company’s stock worth $151,000 after acquiring an additional 3,896 shares during the last quarter. Hedge funds and other institutional investors own 25.30% of the company’s stock.
About Akcea Therapeutics
Akcea Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, which is designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase III clinical study for the treatment of familial partial lipodystrophy.
Recommended Story: Reverse Stock Split
Receive News & Ratings for Akcea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akcea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.